A detailed history of Cetera Investment Advisers transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Cetera Investment Advisers holds 7,102 shares of BPMC stock, worth $671,849. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,102
Previous 6,910 2.78%
Holding current value
$671,849
Previous $744,000 11.83%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$84.1 - $120.5 $16,147 - $23,136
192 Added 2.78%
7,102 $656,000
Q2 2024

Aug 22, 2024

SELL
$85.18 - $108.78 $120,188 - $153,488
-1,411 Reduced 16.96%
6,910 $744,000
Q1 2024

May 24, 2024

BUY
$73.17 - $99.79 $608,847 - $830,352
8,321 New
8,321 $789,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.65B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.